1. Steen VD, et al. Arthritis Rheum 1994;37:1283–9.
2. Khanna D, et al. Arthritis Rheum 2011;63:3078–85.
3. Goh NS, et al. Arthritis Rheumatol 2017;69:1670–8.
4. Distler O et al. N Engl J Med 2019;380:2518–28.

The SENSCIS trial was funded by Boehringer Ingelheim. Editorial and formatting assistance, supported financially by Boehringer Ingelheim, was provided by Elizabeth Ng and Wendy Morris of FleishmanHillard Fishburn, London, UK during preparation of this poster. The authors were fully responsible for all content and editorial decisions, were involved at all stages of poster development and have approved the final version. Boehringer Ingelheim was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations. The authors received no direct compensation related to the development of this poster. Oliver Distler reports grants and personal fees from Actelion, Bayer, Boehringer Ingelheim, and Mitsubishi; personal fees from AbbVie, Acceleron Pharma, Anamar, Amgen, Baecon Discovery, Blade Therapeutics, Catenion, CSL Behring, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, Glenmark Pharma, GlaxoSmithKline, Inventiva, Italfarmaco, IQVIA, Lilly, Medac, Medscape, Menarini, Mepha, Merck Sharp & Dohme, Novartis, Roche, Sanofi, Target BioScience, and UCB; personal fees and non-financial support from Pfizer; and holds patent mir-29 on the treatment of SSc, assigned to the University of Zurich. Masataka Kuwana reports grants and personal fees from Actelion Pharmaceuticals and personal fees from Bayer, Chugai, Corbus, CSL Behring and Reata Pharmaceuticals.